Short-Time Infusion of Oxaliplatin (Eloxatin®) in Combination with Capecitabine (Xeloda®) in Patients with Advanced Colorectal Cancer

Acta Oncologica

Volumn 42, Issue 8, 2003, Pages 832-836

  Pfeiffer, Per ^a   Hahn, Pernille ^a   Jensen, Helle Anita ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; LARYNGOPHARYNGEAL DYSAESTHESIA; LARYNX SPASM; LEUKOPENIA; MALE; NAUSEA; NEUROPATHY; NEUROTOXICITY; PARESTHESIA; PRIORITY JOURNAL; SENSORY NEUROPATHY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES;

EID: 0345865035     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310015894     Document Type: Article

References (19)

1. Ragnhammar P, Hafstrom L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001; 40: 282-308.
2. Cunningham D, Pyrhönen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-12.
3. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-7.
4. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 2000; 343: 905-14.
5. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomised trial of oxaliplatin added to chronomodulated fluorouracil- leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-47.
6. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
7. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (oxa) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21: Abstract 512.
8. Borner MM, Dietrich D, Stupp R, et al. Phase II study of capecitabine and oxaliplatin in first-and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20: 1759-66.
9. Diaz-Rubio E, Evans TRJ, Tabernero J, et al. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumours. Ann Oncol 2002; 13: 558-65.
10. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-92.
11. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-106.
12. Glimelius B, Jacobsen A, Graf W, et al. Bolus injection (2-4 minutes) versus short-term (10-20 minutes) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomized trial. Eur J Cancer 1998; 34: 674-8.
13. Glimelius B, Ristamaki R, Kjaer M, et al. Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol 2002; 13: 1868-73.
14. Chollet P, Bensmäine MA, Brienza, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer, Ann Oncol 1996; 7: 1065-70.
15. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favourable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-75.
16. Zeuli M, Costanzo ED, Sdrobolini A, et al. Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. Ann Oncol 2001; 12: 1737-41.
17. Scheithauer W, Kornek GV, Raderer M. et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21: 1307-12.
18. Rothenberg ML, Oza AM, Burger B, et al. Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin. Proc Am Soc Clin Oncol 2003; 22: Abstract 1011.
19. Tournigand C, Louvet C, Andre T, et al. FOLFIRI followed by FOLFOX or FOLFOX followed by FOLFIRI in metastatic colorectal cancer. Proc Am Soc Clin Oncol 2001; 20: Abstract 494.